This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Empliciti
  • /
  • Study of Bortezomib and Dexamethasone With or With...
Clinical trial

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Read time: 1 mins
Last updated:1st Nov 2011

The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens [progression free survival (PFS)].

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment: 185
Study Start Date: November 2011
Estimated Study Completion Date: April 2016
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)

- Experimental:
Arm A: Elotuzumab + Bortezomib + Dexamethasone
- Active Comparator: Arm B: Bortezomib + Dexamethasone

Category Value
Study start date 2011-11-01

View full details